跳至主要内容
临床试验/NCT04174456
NCT04174456Unknown不适用

Olmesartan Effect on Myocardial Viability of Patients With Dilated Cardiomyopathy

Dong-A University1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2019年12月1日最近更新:
适应症

试验速览

阶段
不适用
入组人数
40
试验地点
1
主要终点
Rate of glucose metabolism

研究概览

简要总结

The study proceeds with prospective, randomized, open and controlled clinical trials. The subject of the investigator's study was the first patient diagnosed with dilated cardiomyopathy. Subjects who agreed to participate in the study and were determined to meet the selection / exclusion criteria were randomly assigned to each group, and the experimental group was treated with 20 mg of olmesartan and 5 mg of rosuvastatin for 6 months, and the control group is treated with 40 mg of valsartan and 5 mg of rosuvastatin.

详细描述

Myocardial viability plays an important role in improving the function of the heart. To date, the most reproducible and objective method has been established as a method or tool for assessing myocardial viability.

Olmesartan is known to have the strongest inhibitory ability of angiotensin receptors compared with other angiotensin receptor binding inhibitors. Research has been reported that statin drugs may help improve vascular endothelial function, and several researchers have suggested that these mechanisms may affect the improvement of myocardial survival. In addition, studies have shown that angiotensin receptor binding inhibitors and statins may improve left ventricular function in patients with left ventricular function. However, since the studies did not assess myocardial survival, the mechanisms could not be clearly identified.

The purpose of this study is to investigate the effect of olmesartan on myocardial survival in patients with dilated cardiomyopathy who have left ventricular dysfunction.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Other
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • dilated cardiomyopathy

排除标准

  • contraindication to angiotensin receptor blocker
  • cardiogenic shock
  • sensitive to rosuvastatin
  • liver cirrhosis more than Child class B

结局指标

主要结局

Rate of glucose metabolism

时间窗: 6 month

data from fludeoxyglucose positron emission tomography

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Kyungil Park

Associate professor

Dong-A University

研究点 (1)

Loading locations...

相似试验